TECOS: No Increase in HF Hospitalization With SitagliptinTECOS: No Increase in HF Hospitalization With Sitagliptin
Top-line results of the TECOS cardiovascular outcomes trial with sitagliptin indicate no increased risk of heart failure with the drug, Merck has announced. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Endocrinology | Health | Heart | Heart Failure | Januvia | Merck